RadioGel is an yttrium-90 (90Y) based injectable Precision Radionuclide Therapy (PRnT) device
for the treatment of cancerous tumors in animals (IsoPet®) and humans (RadioGel™).
Precision Radionuclide Therapy (PRnT) uses highly localized radiation to destroy,
cancerous tumors by placing a radioactive isotope directly inside the treatment
area using the company’s proprietary hydrogel technology.
Radiogel™ is a hydrogel liquid containing tiny Yttrium-90 (Y-90) phosphate microparticles that may be administered directly into a tumor.
The hydrogel is an yttrium-90 carrier at room temperature that gels within the tumor interstitial spaces after injection to keep the radiation sources safely in place. The short-range
beta radiation from yttrium-90 localizes the dose within the treatment area so that normal organs and tissues are not adversely affected.
The Isopet® Solutions division utilized university veterinary hospitals to demonstrate the safety and therapeutic effectiveness for different animal cancers. Testing on feline sarcoma at
the Washington State University was completed in 2018 and testing on canine soft tissue sarcomas at the University of Missouri was completed in 2019.
IsoPet® Therapy is readily available at The University of Missouri and select Regional Clinics.
Learn More
( Mike Korenko, Sc.D • CEO • President | September 14, 2022 Press Release )
Richland WA, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc announced today that they filed a patent application on their hydrogel component of IsoPet/RadioGel in the USA (16309: 17/943,311) and internationally (16389: PCT/US22/43274) under The Patent Cooperation Treaty (PCT).
Over the last eighteen months our team has worked with polymer contracting experts to optimize our hydrogel component. Our objectives were to maximize production
output, to refine our specifications to yield the optimum gelation and resorption characteristics, to demonstrate reproducibility and to ensure that any residual solvents were minor and well
below the FDA specifications limits for human therapy.